Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1568-1571

  Quaye, Nerteley ^a   Cole, Michelle J ^a   Ison, Catherine A ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Carbapenems; Cephalosporins; Gonorrhoea

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; PENICILLIN DERIVATIVE; SPECTINOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; EVALUATION STUDY; GONORRHEA; INFECTION RESISTANCE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; CLASSIFICATION; DRUG EFFECTS; GENETICS; HUMAN; IC50; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTILOCUS SEQUENCE TYPING;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFIXIME; GONORRHEA; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; NEISSERIA GONORRHOEAE;

EID: 84903899178     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt537     Document Type: Article

References (17)

1. PHE. Sexually Transmitted Infections Annual Data. http://www.hpa.org. uk/Topics/InfectiousDiseases/InfectionsAZ/STIs/STIsAnnualDataTables/(17 December 2013, date last accessed).
2. WHO. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections-2008. http://www.who.int/reproductivehealth/publications/rtis/2008_STI_estimates.pdf (17 December 2013, date last accessed).
3. WHO. Guidelines for the Management of Sexually Transmitted Infections. ISBN 92 4 154626 3. 2003. http://www.who.int/hiv/pub/sti/en/STIGuidelines2003.pdf (17 December 2013, date last accessed).
4. Ison CA, Town K, Obi C et al. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. Lancet Infect Dis 2013; 13: 762-8.
5. Unemo M, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution and lessons learned for the future. Ann N Y Acad Sci 2011; 1230: E19-28.
6. Bignell C, Fitzgerald M. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011; 22: 541-7.
7. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013; 24: 85-92.
8. Majumdar AK, Musson DG, Birk KL et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-11.
9. Livermore DM, Alexander S, Marsden B et al. Activity of ertapenem against Neisseria gonorrhoeae. J Antimicrob Chemother 2004; 54: 280-1.
10. Unemo M, Golparian D, Limnios A et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhoea? Antimicrob Agents Chemother 2012; 56: 3603-9.
11. Unemo M, Golparian D, Nicholas R et al. High-level cefixime-and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56: 1273-80.
12. Unemo M, Fasth O, Fredlund H et al. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009; 6: 1142-51.
13. Chisholm SA, Alexander S, Desouza-Thomas L et al. Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales. J Antimicrob Chemother 2011; 66: 2509-12.
14. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhoea. Future Microbiol 2012; 7: 1401-22.
15. Biedenbach DJ, Turner LL, Jones RN et al. Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains. Diagn Microbiol Infect Dis 2012; 74: 204-6.
16. Golparian D, Fernandes P, Ohnishi M et al. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother 2012; 56: 2739-42.
17. Hook E III, Oldach D, Jamieson B et al. A phase 2 study to evaluate the efficacy and safety of single dose solithromycin (CEM-101) for the treatment of patients with uncomplicated urogenital gonorrhoea. In: Abstracts of the Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 2013. Abstract O274. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.